Trigeminal neuropathy after tozinameran vaccination against COVID-19 in postmicrovascular decompression for trigeminal neuralgia: illustrative case.
COVID-19
case report
microvascular decompression
trigeminal neuropathy
vaccination
Journal
Journal of neurosurgery. Case lessons
ISSN: 2694-1902
Titre abrégé: J Neurosurg Case Lessons
Pays: United States
ID NLM: 9918227275606676
Informations de publication
Date de publication:
18 Apr 2022
18 Apr 2022
Historique:
received:
02
03
2022
accepted:
08
03
2022
entrez:
28
10
2022
pubmed:
29
10
2022
medline:
29
10
2022
Statut:
epublish
Résumé
Vaccines against coronavirus disease 2019 have a high level of efficacy and safety across all populations. However, numerous case series have been published on neurological disorders, including Bell's palsy, Guillain-Barre syndrome, transverse myelitis, and multiple sclerosis. The authors presented a case of trigeminal neuropathy after coronavirus vaccination in a patient who had undergone microvascular decompression (MVD) for trigeminal neuralgia (TN). A 77-year-old woman presented with acute trigeminal neuropathy after receiving a Pfizer-BioNtech vaccination (tozinameran) against severe acute respiratory syndrome coronavirus 2. The patient had undergone MVD for TN and the facial pain completely disappeared. One month later, she received the first injection of the tozinameran vaccine. Twelve hours after vaccination, she presented with numbness and pain induced by touching any place on the entire right face. No eruption was observed on her face. The serum herpes zoster virus antibodies were confirmed within the normal range. Magnetic resonance imaging revealed no abnormalities. The authors suspected a right trigeminal neuropathy after vaccination. Administration of carbamazepine and pregabalin improved TN but facial numbness persisted, especially in the mandibular division. The coronavirus is a possible etiology of secondary trigeminal neuropathy in the case of MVD for TN.
Sections du résumé
BACKGROUND
BACKGROUND
Vaccines against coronavirus disease 2019 have a high level of efficacy and safety across all populations. However, numerous case series have been published on neurological disorders, including Bell's palsy, Guillain-Barre syndrome, transverse myelitis, and multiple sclerosis. The authors presented a case of trigeminal neuropathy after coronavirus vaccination in a patient who had undergone microvascular decompression (MVD) for trigeminal neuralgia (TN).
OBSERVATIONS
METHODS
A 77-year-old woman presented with acute trigeminal neuropathy after receiving a Pfizer-BioNtech vaccination (tozinameran) against severe acute respiratory syndrome coronavirus 2. The patient had undergone MVD for TN and the facial pain completely disappeared. One month later, she received the first injection of the tozinameran vaccine. Twelve hours after vaccination, she presented with numbness and pain induced by touching any place on the entire right face. No eruption was observed on her face. The serum herpes zoster virus antibodies were confirmed within the normal range. Magnetic resonance imaging revealed no abnormalities. The authors suspected a right trigeminal neuropathy after vaccination. Administration of carbamazepine and pregabalin improved TN but facial numbness persisted, especially in the mandibular division.
LESSONS
CONCLUSIONS
The coronavirus is a possible etiology of secondary trigeminal neuropathy in the case of MVD for TN.
Identifiants
pubmed: 36303493
doi: 10.3171/CASE22101
pii: CASE22101
pmc: PMC9379720
doi:
pii:
Types de publication
Journal Article
Langues
eng
Références
Headache. 2021 Mar;61(3):560-562
pubmed: 33749854
Headache. 2020 Sep;60(8):1806-1811
pubmed: 32521039
J Neurosurg. 2020 Jul 3;:1-8
pubmed: 32619989
ACS Chem Neurosci. 2020 Apr 1;11(7):995-998
pubmed: 32167747
BMJ Case Rep. 2021 Jun 21;14(6):
pubmed: 34155020
J Neurol. 2022 Mar;269(3):1093-1106
pubmed: 34480607
Lancet. 2021 Jan 9;397(10269):72-74
pubmed: 33306990
Praxis (Bern 1994). 2002 Jan 30;91(5):159-62
pubmed: 11865774
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
N Engl J Med. 2020 Nov 12;383(20):1920-1931
pubmed: 32663912
J Neurovirol. 2022 Feb;28(1):181-182
pubmed: 34870807
Lancet Infect Dis. 2022 Jan;22(1):64-72
pubmed: 34411532
J Neurol. 2022 Jan;269(1):55-58
pubmed: 34115170